Pain impressively modulated by—and better understood with—immersive VR

Virtual reality can help quell perceptions of pain as well as dampening the prickling sensations that patients with nerve damage sometimes experience upon being touched.

The study behind the findings is posted in the Journal of Pain and publicized in a news release sent by the University of Plymouth in the U.K.

Comparing the use of 3-D, 360-degree scenes of the frigid Arctic with 2D versions of the same scenes—“sham VR”—Sam Hughes, PhD, and colleagues found the latter significantly less effective.

The project shows that “exposure to an immersive virtual reality environment can modulate perceptual correlates of endogenous pain modulation and secondary hyperalgesia in a human surrogate pain model,” the authors write. “These results suggest that virtual reality could provide a novel mechanism-driven analgesic strategy in patients with altered central pain processing.”

To this Hughes adds in the news release:

It’s brilliant that we’ve seen these results as it shows more evidence that virtual reality can not only reduce pain perception in human models of chronic pain but also gives us insight into the mechanisms behind this effect. The next step of course is to conduct the study with people who experience chronic pain to see if it works for them. If it does work, it could be a really helpful in forming part of ongoing pain management by helping to target the dysfunctions in the brain that underpin chronic pain.

Study here, release here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.